KR101966630B1 - 흡입에 적당한 산화된 아비딘의 약제학적 조성물 - Google Patents

흡입에 적당한 산화된 아비딘의 약제학적 조성물 Download PDF

Info

Publication number
KR101966630B1
KR101966630B1 KR1020147001707A KR20147001707A KR101966630B1 KR 101966630 B1 KR101966630 B1 KR 101966630B1 KR 1020147001707 A KR1020147001707 A KR 1020147001707A KR 20147001707 A KR20147001707 A KR 20147001707A KR 101966630 B1 KR101966630 B1 KR 101966630B1
Authority
KR
South Korea
Prior art keywords
biotinylated
composition
group
avidin
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147001707A
Other languages
English (en)
Korean (ko)
Other versions
KR20140047668A (ko
Inventor
리타 데 산티스
Original Assignee
알파시그마 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알파시그마 에스.피.에이. filed Critical 알파시그마 에스.피.에이.
Publication of KR20140047668A publication Critical patent/KR20140047668A/ko
Application granted granted Critical
Publication of KR101966630B1 publication Critical patent/KR101966630B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147001707A 2011-08-02 2012-07-25 흡입에 적당한 산화된 아비딘의 약제학적 조성물 Active KR101966630B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006338 2011-08-02
EP11006338.5 2011-08-02
PCT/EP2012/064576 WO2013017494A1 (en) 2011-08-02 2012-07-25 Pharmaceutical composition of oxidised avidin suitable for inhalation

Publications (2)

Publication Number Publication Date
KR20140047668A KR20140047668A (ko) 2014-04-22
KR101966630B1 true KR101966630B1 (ko) 2019-04-09

Family

ID=46581966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001707A Active KR101966630B1 (ko) 2011-08-02 2012-07-25 흡입에 적당한 산화된 아비딘의 약제학적 조성물

Country Status (19)

Country Link
US (1) US9872831B2 (enExample)
EP (1) EP2739314B1 (enExample)
JP (1) JP6019118B2 (enExample)
KR (1) KR101966630B1 (enExample)
CN (1) CN103717239B (enExample)
AU (1) AU2012292229B2 (enExample)
BR (1) BR112014002593B1 (enExample)
CA (1) CA2842276C (enExample)
DK (1) DK2739314T3 (enExample)
EA (1) EA026453B1 (enExample)
ES (1) ES2729549T3 (enExample)
IL (1) IL230597A0 (enExample)
MX (1) MX355177B (enExample)
PH (1) PH12014500193A1 (enExample)
PL (1) PL2739314T3 (enExample)
PT (1) PT2739314T (enExample)
UA (1) UA114482C2 (enExample)
WO (1) WO2013017494A1 (enExample)
ZA (1) ZA201401921B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
EP3458097A4 (en) * 2016-05-19 2020-01-08 University of Miami TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209519A1 (en) * 2009-02-16 2010-08-19 National Taiwan University Pharmaceutical composition for inhalation delivery and fabrication method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
AU691514B2 (en) 1993-07-19 1998-05-21 Amgen, Inc. Stabilization of aerosolized proteins
DE69830305T2 (de) * 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
HK1042234A1 (zh) * 1999-04-13 2002-08-09 Nektar Therapeutics 向肺部施加乾粉配方以治疗不育症
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ITRM20030196A1 (it) * 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
MX2007007378A (es) * 2004-12-17 2007-08-14 Cipla Ltd Compuestos y composiciones farmaceuticas.
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
CN101772353B (zh) * 2007-08-02 2013-03-06 希格马托制药工业公司 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209519A1 (en) * 2009-02-16 2010-08-19 National Taiwan University Pharmaceutical composition for inhalation delivery and fabrication method thereof

Also Published As

Publication number Publication date
CN103717239A (zh) 2014-04-09
ES2729549T3 (es) 2019-11-04
IL230597A0 (en) 2014-03-31
CN103717239B (zh) 2017-08-01
MX355177B (es) 2018-04-09
US20140134106A1 (en) 2014-05-15
ZA201401921B (en) 2015-05-27
UA114482C2 (uk) 2017-06-26
CA2842276C (en) 2020-11-24
AU2012292229A1 (en) 2014-02-13
DK2739314T3 (da) 2019-06-24
US9872831B2 (en) 2018-01-23
EA026453B1 (ru) 2017-04-28
JP2014521675A (ja) 2014-08-28
BR112014002593A2 (pt) 2017-03-01
KR20140047668A (ko) 2014-04-22
NZ620202A (en) 2016-05-27
MX2014001176A (es) 2014-07-14
PH12014500193A1 (en) 2014-03-24
CA2842276A1 (en) 2013-02-07
AU2012292229B2 (en) 2017-08-03
JP6019118B2 (ja) 2016-11-02
EP2739314B1 (en) 2019-05-22
BR112014002593B1 (pt) 2022-11-29
PT2739314T (pt) 2019-06-21
EA201490401A1 (ru) 2014-05-30
EP2739314A1 (en) 2014-06-11
PL2739314T3 (pl) 2019-09-30
WO2013017494A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
Li et al. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Wang et al. MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair
Groneberg et al. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport
CA3120647A1 (en) Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
CN107530436A (zh) 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
ES2770073T5 (es) Uso terapéutico de proteínas morfogenéticas óseas
KR20130051754A (ko) 신규한 유전자 전달용 조성물
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
TWI725947B (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
US20170304400A1 (en) Methods for preventing fibrosis using cxcr4 and/or cxcr7 binding agents
KR101966630B1 (ko) 흡입에 적당한 산화된 아비딘의 약제학적 조성물
EP3173094B1 (en) Use of interleukin-1 receptor antagonist for preparing a medicament for use in preventing or treating epithelium trauma of intestinal mucosa
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
US20130252904A1 (en) Compositions and methods for treating cancer
US12042485B2 (en) Methods of minimizing cancer metastasis
HK1194002B (en) Pharmaceutical composition of oxidised avidin suitable for inhalation
TW200902034A (en) Effective treatment of tumors and cancer with prodrugs of triciribine
HK1194002A (en) Pharmaceutical composition of oxidised avidin suitable for inhalation
NZ620202B2 (en) Pharmaceutical composition of oxidised avidin suitable for inhalation
JP2002540172A (ja) 腫瘍治療の増強のためのスフィンゴミエリン含有調製物
WO2022226177A1 (en) Compositions of interleukin-1 receptor antagonist
Gunawan et al. Conventional and functionalised nanostructured lipid carriers for pulmonary-targeted delivery systems
Dhand Lung cancer inhalation therapeutics
CN118718000A (zh) 药物组合物及其在制备治疗肾癌的药物中的用途
WO2020232638A1 (zh) 一种抗体偶联物及其药物组合物的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170609

Comment text: Request for Examination of Application

PN2301 Change of applicant

Patent event date: 20171228

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180716

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181122

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190323

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190402

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220223

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230223

Start annual number: 5

End annual number: 5